Literature DB >> 12661915

Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation.

Atsuko Nose1, Yasukiyo Mori, Yoko Uchiyama-Tanaka, Noriko Kishimoto, Katsuya Maruyama, Hiroaki Matsubara, Toshiji Iwasaka.   

Abstract

In the development of diabetic nephropathy, angiotensin (Ang) II is thought to exert numerous actions on the glomerulus, and especially on the mesangium. However, the role(s) played by Ang II in the glucose metabolism per se in mesangial cells remains unclear. Ang II, at least via its type 1 receptor (AT1-R)-mediated effect, phosphorylates extracellular signal regulated kinase (ERK) by transactivation of epidermal growth factor receptors (EGF-Rs) via the Ca2+ or protein kinase C (PKC) pathways. Our objective in the present study was to assess the effect of Ang II on glucose transporter 1 (GLUT1) gene expression and to clarify the involvement of EGF-R in Ang II-mediated GLUT1 mRNA expression in glomerular mesangial cells. The results showed that Ang II upregulated GLUT1 mRNA accumulation in a time- and dose-dependent manner (peaking at 12 h; approximately 3.8-fold vs. control), and this upregulation was completely inhibited by the PKC inhibitor calphostin-C. The Ang Il-induced GLUT1 expression was significantly inhibited by the EGF-R inhibitor AG1478 (approximately 80% inhibition), by inactivation of ERK by PD98059, and by pretreatment with heparin and the metalloproteinase (MMP) inhibitor batimastat. On the other hand, phorbol ester markedly upregulated GLUT1 mRNA (approximately 8.6-fold). Batimostat and AG1478 significantly reduced the phorbol ester-induced GLUT1 mRNA expression (approximately 72 and approximately 69% inhibition, respectively). In conclusion, PKC-mediated heparin-binding (HB)-EGF/EGF transactivation followed by ERK activation plays a predominant role in the induction of GLUT1 expression by Ang II.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661915     DOI: 10.1291/hypres.26.67

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  16 in total

Review 1.  Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment.

Authors:  Chelsey J Forbess Smith; Sheila Fallon Friedlander; Monica Guma; Arthur Kavanaugh; Christina D Chambers
Journal:  Birth Defects Res       Date:  2017-04-12       Impact factor: 2.344

Review 2.  Glucose transporters in diabetic nephropathy.

Authors:  Frank C Brosius; Charles W Heilig
Journal:  Pediatr Nephrol       Date:  2005-02-17       Impact factor: 3.714

Review 3.  Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy.

Authors:  Eain M Cornford; Shigeyo Hyman
Journal:  NeuroRx       Date:  2005-01

4.  Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways.

Authors:  Mahefatiana Andrianifahanana; Danielle M Hernandez; Xueqian Yin; Jeong-Han Kang; Mi-Yeon Jung; Youli Wang; Eunhee S Yi; Anja C Roden; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2016-08-01       Impact factor: 5.191

5.  Insulin Signaling Via Progesterone-Regulated Insulin Receptor Substrate 2 is Critical for Human Uterine Decidualization.

Authors:  Alison M Neff; Jie Yu; Robert N Taylor; Indrani C Bagchi; Milan K Bagchi
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

6.  Activation of retinal Müller cells in response to glucose variability.

Authors:  Fabiana Picconi; Mariacristina Parravano; Francesca Sciarretta; Chiara Fulci; Michela Nali; Simona Frontoni; Monica Varano; Anna Maria Caccuri
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

7.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Authors:  Shizuka Aritomi; Kazumi Niinuma; Tetsuya Ogawa; Tomoyuki Konda; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-17       Impact factor: 2.801

Review 8.  Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.

Authors:  Michael W Ronellenfitsch; Joachim P Steinbach; Wolfgang Wick
Journal:  Target Oncol       Date:  2010-09-19       Impact factor: 4.493

Review 9.  The epidermal growth factor receptor pathway in chronic kidney diseases.

Authors:  Laura R Harskamp; Ron T Gansevoort; Harry van Goor; Esther Meijer
Journal:  Nat Rev Nephrol       Date:  2016-07-04       Impact factor: 28.314

10.  Live imaging of GLUT2 glucose-dependent trafficking and its inhibition in polarized epithelial cysts.

Authors:  Merav Cohen; Daniel Kitsberg; Sabina Tsytkin; Maria Shulman; Benjamin Aroeti; Yaakov Nahmias
Journal:  Open Biol       Date:  2014-07       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.